# Body Composition Sub-study of the D2EFT Trial

> **NCT03675815** · PHASE4 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 155 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Darunavir (DRV) 800 milligram (MG) Oral Tablet
- **DRUG:** Ritonavir 100 MG Oral Tablet
- **DRUG:** N(t)RTIs
- **DRUG:** Dolutegravir 50 MG Oral Tablet
- **DRUG:** TDF 300 MG Oral Tablet
- **DRUG:** 3TC 300 MG Oral Tablet
- **DRUG:** FTC 200 MG Oral Cap

## Key facts

- **NCT ID:** NCT03675815
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-05
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-01-15
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03675815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03675815, "Body Composition Sub-study of the D2EFT Trial". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03675815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*